GEN Exclusives

More »

GEN News Highlights

More »
Sep 11, 2007

Nabi Divests Biologics Unit for $185M to Biotest

  • Nabi Biopharmaceuticals is divesting its Nabi Biologics strategic business unit (SBU) to Biotest Pharmaceuticals for $185 million.

    Biotest will thus acquire the Biologics SBU’s products including Nabi-HB®, a marketed therapy indicated to prevent hepatitis B infection. It will also gain all the plasma business assets such as the plasma protein production plant and nine FDA-certified plasma collection centers across the U.S.

    “With the acquisition of Nabi Biologics, we have found the ideal complement for our European plasma protein business and have become a global player in the industry,” comments Gregor Schulz, chairman of the management board of Biotest.

    After the closing of the transaction, Nabi Biopharmaceuticals will operate its Pharmaceuticals SBU from its existing Rockville, MD facility, which will become its new headquarters.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?